AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago.
Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio.
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call.
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago.
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.